Home / Investors
Investors
Back human cell intelligence.
Pharma already pays for CardioVive, and every study adds real human data to CytoHub.AI.
Why CytoHub
Four reasons the advantage compounds.
Revenue first
Pharma and biotech customers pay for cardiac safety studies today. The data business is built on commercial work, not on promises.
A feedback loop
Every paid study adds real human data to one map of human cell biology. As prediction comes online, better predictions design better experiments and bring more studies, so the advantage compounds.
Defensible process
Eight patent families, an exclusive MSU license and bioreactor know-how held as a trade secret protect how the data is made.
One stack, many organs
Robotics, data capture and AI built for the heart extend to the brain next, and then to other human tissues.
Why now
Every year, a door opened.
- 2022Animal tests optional
FDA Modernization Act 2.0.
- 2023Adult-grade tissue
EMM2/1 maturation published.
- 2025NIH backs human models
NIH prioritises human-based research.
- 2026FDA guidance
Draft guidance on alternatives to animal testing; immunoid standards published.
Backed by
Investors, grants and programs.
CytoHub is based at J&J JLABS in San Diego. Cardia Therapeutics, our therapeutic program, is financed separately.
This page is for information only. It is not an offer to sell, or a solicitation of an offer to buy, any securities. Statements about plans and products in development are forward-looking and may change.